Apr 16 |
Nexalin Technology files to offer common stock worth $5.65M
|
Apr 10 |
Nexalin Technology CEO Provides Letter to Shareholders
|
Apr 9 |
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
|
Apr 4 |
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
|
Apr 4 |
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
|
Apr 2 |
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
|
Apr 2 |
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
|
Mar 30 |
Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)
|
Mar 28 |
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
|
Mar 14 |
Nexalin Technology commences sales of gen-2 neurostimulation device in Oman
|